The application of new molecular tools, such as massive parallel sequence technologies, has provided new diagnostic markers, including immunohistochemical markers (FOSB, CAMTA1, YAP1, and MYC), recurrent gene fusions (e.g., those involving FOS, FOSB, YAP1, and WWTR1), and the opportunity for further refinements of the classification of bone vascular neoplasms [1,2,3,4,5]. This evidence concerns the gene YAP1 and vascular bone neoplasm.